PURPOSE
To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients.
EXPERIMENTAL DESIGN
Preclinical modeling in syngeneic t...
I. Teige, K. Rohrberg, A. Carneiro et al.· Clinical Cancer Research· 0 citations
ODM-209 showed activity in heavily pretreated participants with mCRPC, particularly those with activating AR-LBD mutations, with an expected AE profile.
A. Bernard-Tessier, I. Spanggaard, T. Utriainen et al.· European Journal of Cancer· 0 citations
Abstract Purpose: The Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (TEMPLE) study was a phase Ib/II trial evaluating the safety, tolerability, and efficacy of atezolizumab combined with thiopurine therapy in patients with metastatic solid tumors, aiming to increase tumor mutational burden (TMB) through sing...
C. F. Secher, M. Højgaard, I. Spanggaard et al.· Cancer Research Communicatio...· 0 citations
The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
HERV-K (HML-2) is the most studied transcriptionally active endogenous retrovirus in human cancers, yet immune tolerance and incomplete mechanistic understanding have impeded its clinical use as an immunotherapy target. We hypothesized that rational engineering of the HERV-K envelope putative immunosuppressive do...
M. D. Müller, L. Neukirch, E. Ragonnaud et al.· Journal of Translational Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.